Table 1 Phase II trials of bevacizumab in combination with chemotherapy in metastatic breast cancer
Reference | Number of patients | Therapy | ORR (%) | PFS (months) |
|---|---|---|---|---|
Ramaswamy et al. [6] | 27 (78% HER2-negative) | B + docetaxel | 52 (1st + 2nd line) | 8 |
Chan et al. [7] | 43 (21 evaluable) | B + docetaxel | Approximately 40 (1st line) | NR |
Hurvitz et al. [8] | 69 (67 evaluable; HER2-negative) | B + docetaxel | 48 (1st line) | 8 (TTP) |
Perez et al. [9] | 45 (HER2-negative) | B + docetaxel + capecitabine | 49 (1st line) | 11 |
| Â | Â | Â | 69 (CBR) | Â |
Hoelzer et al. [10] | 61 (57 evaluable) | B + paclitaxel | 42 (1st line) | 15 |
| Â | 58 (54 evaluable) | B + paclitaxel + gemcitabine | 48 | 20 |
Guardino et al. [11] | 21 (17 evaluable) | B + paclitaxel + gemcitabine | 88 (CBR) | NR |
Rugo et al. [12] | 46 | B + ixabepilone (weekly) | 50 (1st line) | NR |
| Â | 45 | B + ixabepione (q3w) | 71 | NR |
| Â | 32 | B + paclitaxel | 56 | NR |
Danso et al. [13] | 49 (27 evaluable; HER2-negative) | B + nab-paclitaxel | 30 (1st line) | 9 |
Conlin et al. [14] | 72 | B + nab-paclitaxel (three dosing schedules) | 42 (1st line) | 9 (TTP) |
| Â | 54 | Â | 42 | 6 |
| Â | 76 | Â | 42 | 8 |
Sledge et al. [15] | 103 | B + capecitabine | 39 (1st line) | NR |
Traina et al. [16] | 29 | B + capecitabine | 31 (various; 10 pts with SD >6 months) | NR |
Dellapasqua et al. [17] | 46 | B + capecitabine + cyclophosphamide | 48 (1st to 3rd line) | 10 (TTP) |
Rochlitz et al. [18] | 41 | B + pegylated liposomal doxorubicin | 23 (1st line) | 8 |